Northern Trust Corp Purchases 30,772 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Northern Trust Corp grew its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 112.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,108 shares of the company’s stock after buying an additional 30,772 shares during the quarter. Northern Trust Corp owned approximately 0.11% of Milestone Pharmaceuticals worth $137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in MIST. Virtu Financial LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $170,000. XTX Topco Ltd bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $80,000. National Bank of Canada FI grew its stake in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after purchasing an additional 11,600 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. 86.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MIST. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. TD Securities cut shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Cowen cut shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Finally, TD Cowen cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $17.00.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock opened at $1.69 on Wednesday. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $2.75. The stock has a market cap of $90.35 million, a PE ratio of -2.09 and a beta of 0.86. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The firm’s 50 day moving average price is $1.13 and its two-hundred day moving average price is $1.69.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.12). As a group, analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.